Doxycycline in the current clinical practice | CMAC

Doxycycline in the current clinical practice

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(1):21-28

​ Zyryanov S.K., Golub A.V., Kozlov R.S.
10.36488/cmac.2020.1.21-28
doxycycline Chlamydia acne rosacea periodontitis borreliosis
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(1):21-28

Abstract

This paper reviews clinical and pharmacological characteristics of doxycycline which is currently indicated for the treatment of some common sexually transmitted infections, pelvic inflammatory diseases, lower respiratory tract infections, several skin infections and periodontitis. This antimicrobial agent still plays an important role in the prevention and treatment of certain vector-borne and particularly dangerous infections.

Sergey K. Zyryanov

City Clinical Hospital #24, Moscow, Russia
RUDN University, Moscow, Russia

Alexey V. Golub

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Zhanel G.G., Homenuik K., Nichol K., Noreddin A., Vercaigne L., Embil J., et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. DOI: 10.2165/00003495-200464010-00005
  • 2. Shapiro L.E., Knowles S.R., Shear N.H. Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol. 1997;133(10):1224-1230. PMID: 9382560
  • 3. Smith K., Leyden J.J. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329-1342. DOI: 10.1016/j.clinthera.2005.09.005
  • 4. Workowski K.A., Berman S. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110. PMID: 21160459
  • 5. Perepanova T.S., Kozlov R.S., Rudnov V.A., Sinjakova L.A. Antimicrobial therapy and prevention of infections of the kidneys, urinary tract and male genital organs. Federal clinical guidelines. M.: "Prima-print"; 2017. 72 p. Russian.
  • 6. Nikonov A.P., Ascaturova O.R. Infections in obstetrics and gynecology. A practical guide to the diagnosis and antimicrobial chemotherapy. M.: Borges; 2003. 56 p. Russian.
  • 7. Horner P. Chlamydia (uncomplicated, genital). BMJ Clin Evid. 2010;2010:1607. PMID: 21718568
  • 8. Horner P. The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection. Sex Transm Infect. 2006;82(4):340-343. DOI: 10.1136/sti.2005.019158
  • 9. Tobin J.M., Harindra V., Mani R. Which treatment for genital tract Chlamydia trachomatis infection? Int J STD AIDS. 2004;15(11):737-739. DOI: 10.1258/0956462042395096
  • 10. Lau C.Y., Qureshi A.K. Azithromycin versus doxycycline for genital Chlamidial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002;29(9):497-502. DOI: 10.1097/00007435-200209000-00001
  • 11. Haggerty C.L., Taylor B.D. Mycoplasma genitalium: an emerging cause of pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2011;2011:959816. DOI: 10.1155/2011/959816
  • 12. Jaiyeoba O., Lazenby G., Soper D.E. Recommendations and rationale for the treatment of pelvic inflammatory disease. Expert Rev Anti Infect Ther. 2011;9(1):61-70. DOI: 10.1586/eri.10.156
  • 13. Piyadigamage A., Wilson J. Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy. Sex Transm Infect. 2005;81(3):233-235. DOI: 10.1136/sti.2004.012377
  • 14. Kozlov R.S., Dekhnich A.V. Handbook of antimicrobial chemotherapy. Smolensk: IACMAC, 2010. 416 p. Russian.
  • 15. Stratchounski L.S., Belousov Yu.B., Kozlov S.N. A practical guide to anti-infectious chemotherapy. Smolensk: IACMAC; 2007. 464 p. Russian.
  • 16. Savaris R.F., Teixeira L.M., Torres T.G., Edelweiss M.I., Moncada J., Schachter J. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol. 2007;110(1):53-60. DOI: 10.1097/01.AOG.0000268801.90261.27
  • 17. Penney G.C., Thomson M., Norman J., McKenzie H., Vale L., Smith R., et al. A randomised comparison of strategies for reducing infective complications of induced abortion. Br J Obstet Gynaecol. 1998;105(6):599-604. DOI: 10.1111/j.14710528.1998.tb10173.x
  • 18. Van Eyk N., van Schalkwyk J. Antibiotic prophylaxis in gynaecologic procedures. J Obstet Gynaecol Can. 2012;34(4):382-391. DOI: 10.1016/S1701-2163(16)35222-7
  • 19. Achilles S.L., Reeves M.F. Prevention of infection after induced abortion: release date October 2010: SFP guideline 2010. Contraception. 2011;83(4):295-309. DOI: 10.1016/j.contraception.2010.11.006
  • 20. Low N., Mueller M., Van Vliet H.A., Kapp N. Perioperative antibiotics to prevent infection after first-trimester abortion. Cochrane Database Syst Rev. 2012;3:CD005217. DOI: 10.1002/14651858.CD005217.pub2
  • 21. Babaeinejad S., Khodaeiani E., Fouladi R.F. Comparison of therapeutic effects of oral doxycycline and azithromycin in patient with moderate acne vulgaris: What is the role of age? J Dermatolog Treat. 2011;22(4):206-210. DOI: 10.3109/09546631003762639
  • 22. Kus S., Yucelten D., Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2005;30(3):215-220. DOI: 10.1111/j.13652230.2005.01769.x
  • 23. Kircik L.H. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drug Dermatol. 2010;9(11):1407-1411.
  • 24. Scheinfeld N., Berk T. A review of the diagnosis and treatment of rosacea. Postgrad Med. 2010;122(1):139-143. DOI: 10.3810/pgm.2010.01.2107
  • 25. Bikowski J.B. Treatment of rosacea with doxycycline monohydrate. Cutis. 2000;66(2):149-152. PMID: 10955198
  • 26. Valentin S., Morales A., Sanchez J.L., Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129-140. DOI: 10.2147/ccid.s4296
  • 27. van Zuuren E.J., Kramer S., Carter B., Graber MA, Fedorowicz Z. Interventions for rosacea. Cochrane Database Syst Rev. 2011;3:CD003262. DOI: 10.1002/14651858.CD003262.pub4
  • 28. Torresani C., Pavesi A., Manara G.C. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36(12):938-946. DOI: 10.1046/j.13654362.1997.00301.x
  • 29. Akhyani M., Ehsani A.H., Ghiasi M., Jafari A.K. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47(3):284288. DOI: 10.1111/j.1365-4632.2008.03445.x
  • 30. Buchmann R., Muller R.F., Van Dyke T.E., Lange D.E. Change of antibiotic susceptibility following periodontal therapy. A pilot study in aggressive periodontal disease. J Clin Periodontol. 2003;30(3):222-229. DOI: 10.1034/j.1600051x.2003.10196.x
  • 31. Bokor-Bratic M., Brkanic T. Clinical use of tetracyclines in the treatment of periodontal diseases. Med Pregl. 2000;53(56):266-271. PMID: 11089368
  • 32. Haffajee A.D., Socransky S.S., Gunsolley J.C. Systemic antiinfective periodontal therapy. A systematic review. Ann Periodontol. 2003;8(1):115-181. DOI: 10.1902/annals.2003.8.1.115
  • 33. Akincibay H., Orsal S.O., Sengün D., Tözüm T.F. Systemic administration of doxycycline vs. metronidazole plus amoxicillin in the treatment of localized aggressive periodontitis: a clinical and microbiological study. Quintessence Int. 2008;39(2):e3339. PMID: 18567166
  • 34. Pestel M. Doxycycline in the treatment of respiratory tract infections. Results of a pan-European multi-center trial. Chemotherapy. 1975;21(Suppl. 1):91-108. DOI: 10.1159/000221895
  • 35. Ivanchik N.V., Chagaryan А.N., Sukhorukova М.V., Kozlov R.S., Dekhnich А.V., Krechikova О.I., et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study «PEHASus 2014-2017» Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(3):230-237. Russian. DOI: 10.36488/cmac.2019.3.230-237
  • 36. Sinopalnikov A.I., Kozlov R.S. Community-acquired respiratory tract infections. A guide for doctors. M.: Prem'er MT, Nash Gorod, 2007. 352 p. Russian.
  • 37. Ekaterinburg Research Institute of Viral Infections of The Federal Service on Customers’ Rights Protection and Human Wellbeing Surveillance. “Tick-borne borreliosis”. Available at: www.rospotrebnadzor.ru. Accessed February 2020. Russian.
  • 38. Letter №01/6862-12-32; 19/06/2012 On cases of tick attack in summer health facilities Available at: www.rospotrebnadzor.ru. Accessed February 2020. Russian.
  • 39. Federal Budget Institution of Science «Central Research Institute of Epidemiology» of The Federal Service on Customers Rights Protection and Human Well-being Surveillance. Tick-borne infections: tick-borne encephalitis, tick-borne tick-borne borreliosis (Lyme disease), human granulocytic anaplasmosis, human monocytic ehrlichiosis. More on the analysis. Recommendations for preparing for the study. Available at: www.cmd-online.ru. Accessed February 2020. Russian.
  • 40. Nonspecific prevention of tick-borne viral encephalitis and tick-borne tick-borne borreliosis. M.: The Federal Service on Customers' Rights Protection and Human Well-being Surveillance, 2012. Russian.
  • 41. Wormser G.P., Dattwyler R.J., Shapiro E.D., Halperin J.J., Steere A.C., Klempner M.S., et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic anaplasmosis and babesiosis: Сlinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):10891134. DOI: 10.1086/508667
  • 42. Nadelman R.B., Nowakowski J., Fish D., Falco R.C., Freeman K., McKenna D., et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001;345(2):79-84. DOI: 10.1056/NEJM200107123450201
  • 43. Müllegger R.R., Glatz M. Skin manifestations of lime borreliosis: diagnosis and management. Am J Clin Dermatol. 2008;9(6):355368. DOI: 10.2165/0128071-200809060-00002
  • 44. Dumler J.S., Madigan J.E., Pusterla N., Bakken J.S. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis and treatment. Clin Infect Dis. 2007;45(Suppl. 1):S45-51. DOI: 10.1086/518146
  • 45. Thomas R.J., Dumler J.S., Carlyon J.A. Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and Ehrlichia ewingii ehrlichiosis. Expert Rev Anti Infect Ther. 2009;7(6):709-722. DOI: 10.1586/eri.09.44.
  • 46. American Academy of Pediatrics, Committee on Infectious Diseases. Ehrlichia infections (human ehrlichioses). In: Pickering L., Baker C., Overturf G., Prober C., Eds. Red Book: Report of the Committee on Infectious Diseases. IL, USA: Elk Grove Village; 2003. p. 266-269.
  • 47. Bakken J.S., Dumler J.S. Ehrlichia and Anaplasma species. In: Yu V., Weber R., Raoult D. editors. Antimicrobial therapy and vaccines. 2nd Ed. New York: Apple Trees Productions, 2002. p. 875-882.
  • 48. Letter №01/4730-8-23, 06.06.2008 «On the situation with especially dangerous infectious diseases.» Available at: www.rospotrebnadzor.ru. Accessed February 2020. Russian.
  • 49. Croft A.M. Malaria: prevention in travellers. BMJ Clin Evid. 2007;2007:0903.
  • 50. Ohrt C., Richie T.L., Widjaja H., Shanks G.D., Fitriadi J., Fryauff D.J., et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126(12):963-972. DOI: 10.7326/0003-4819-126-12199706150-00006
  • 51. Taylor W.R, Richie T.L., Fryauff D.J., Picarima H., Ohrt C., Tang D., et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis. 1999;28(1):74-81. DOI: 10.1086/515071
  • 52. World Health Organization. Anthrax in humans and animals. 4th Ed., 2008. Available at www.who.int/csr/resources/publications/anthrax_webs.pdf. Accessed February 2020.
  • 53. Kayabas U., Karahocagil M.K., Ozkurt Z., Metan G., Parlak E., Bayindir Y., et al. Naturally occurring cutaneous anthrax: antibiotic treatment and outcome. Chemotherapy. 2012;58(1):34-43. DOI: 10.1159/000335593
  • 54. Brouillard J.E., Terriff C.M., Tofan A., Garrison M.W. Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents. Pharmacotherapy. 2006;26(1):3-14. DOI: 10.1592/phco.2006.26.1.3
  • 55. Lanza F.L. Esophageal ulceration produced by doxycycline – review of the literature and comparison of the injury from doxycycline hydrate and hydrochloride with that from doxycycline monohydrate. Curr Ther Res Clin Exper. 1988;44(3):475-484.
  • 56. Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Saf. 2000;22(3):237-249. DOI: 10.2165/00002018-20002203000007
  • 57. Practical pharmacy for developing countries. Available at: http://apps.who.int/medicinedocs/documents/s17536en/s17536en.pdf. Accessed February 2020.
  • 58. Yang E.J., Kim M.H., Lim J., Paik N. Oropharyngeal dysphagia in a community-based elderly cohort: the Korean longitudinal study on health and aging. J Korean Med Sci. 2013;28(10):15341539. DOI: 10.3346/jkms.2013.28.10.1534
Views
0 Abstract
0 PDF
0 Crossref citations
Shared